[Therapeutic possibilities in metastatic pheochromocytoma].
Malignant pheochromocytomas are rare. Although 5-year survival is less than 50%, the prognosis varies. Some patients, even those with extensive metastases, have been followed up for many years. If the tumor tissue's uptake is adequate (> 5 Gy/100 mCi) the therapeutic use of 131I-meta-iodobenzylguanidin (131I-MIBG) is at present the therapy of first choice. The use of cytostatic chemotherapy should be limited to patients with rapidly progressive disease.
Vierhapper
H
H
Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für innere Medizin III, Wien, Osterreich.
Raber
W
W
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D010673:Pheochromocytoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine